NCT02740790View on ClinicalTrials.gov

Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 Vaccine in Healthy Females

PHASE2CompletedINTERVENTIONAL
Enrollment

1,200

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

September 30, 2015

Study Completion Date

December 31, 2017

Conditions
Human Papillomavirus
Interventions
BIOLOGICAL

HPV vaccine

Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule

BIOLOGICAL

Placebo

Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule

Trial Locations (1)

Unknown

GuangXi Center for Diseases Control and Prevention, Nanning

All Listed Sponsors
lead

Shanghai Zerun Biotechnology Co.,Ltd

INDUSTRY

NCT02740790 - Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 Vaccine in Healthy Females | Biotech Hunter | Biotech Hunter